GEN.CO : Summary for Genmab A/S - Yahoo Finance

U.S. Markets closed

Genmab A/S (GEN.CO)

Copenhagen - Copenhagen Delayed Price. Currency in DKK
Add to watchlist
1,371.00-53.00 (-3.72%)
At close: 4:59PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1,424.00
Bid1,375.00 x
Ask1,376.00 x
Day's Range1,371.00 - 1,421.00
52 Week Range792.00 - 1,449.00
Avg. Volume273,847
Market Cap82.74B
PE Ratio (TTM)114.08
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of GEN.CO earnings conference call or presentation 22-Feb-17 5:00pm GMT

    Q4 2016 Genmab A/S Earnings Call

  • Reuters2 days ago

    Genmab and J&J's cancer drug set for blockbuster sales this year

    Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday. The $1 billion a year required to achieve blockbuster is now in sight, with net sales of Darzalex -- approved in November 2015 and is marketed by Johnson & Johnson (J&J) -- expected to reach between $1.1 billion and $1.3 billion this year, up from $572 million in 2016, Genmab said. Genmab receives tiered royalties from J&J on its sales and expects to receive Darzalex royalties of between 930 million Danish crowns and 1,100 million crowns ($132 million-$156 million) and 800 million crowns in milestone payments this year.

  • Reuters2 days ago

    Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO

    Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson & Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. "It could work in other blood cancers as well as in solid tumours. Genmab expects sales of Darzalex to surpass $1 billion this year, the company said on Wednesday.